Home / Health / CGM Slashes Diabetes Death Risk
CGM Slashes Diabetes Death Risk
29 Sep
Summary
- Continuous glucose monitors reduce mortality risk by 44% in one year.
- Heart attack and stroke risk drops significantly with CGM use.
- CGM use lowers heart failure hospitalizations by over 50%.
Continuous glucose monitoring (CGM) technology offers a life-saving advantage for individuals with type 2 diabetes who use basal insulin. A significant analysis presented at the European Association for the Study of Diabetes Annual Meeting revealed that initiating CGM use reduces the overall mortality risk by 44% within the first year. This protective effect is sustained, with a 35% lower risk observed after two years compared to non-users.
The research, utilizing anonymized health records from over 140 million Americans, found substantial reductions in cardiovascular complications. Users experienced a 26% lower risk of major cardiovascular events like heart attacks and strokes within the first year. Crucially, hospitalizations due to heart failure saw a remarkable decrease of 54% after one year and 47% after two years for CGM users.
While this observational study indicates a strong correlation, further research is needed to confirm direct causality. Nevertheless, the findings present compelling evidence that CGMs are instrumental in safeguarding patients from life-threatening health issues, extending beyond mere daily data collection.
